Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6367679 | 0.98 | KMT2A (0.55) | KMT2ASMN1; SMN2TSHRALOX15USP2 | |
| SCHEMBL4196193 | 0.87 | KMT2A (0.49) | KMT2ASMN1; SMN2TSHRALOX15USP2 | |
| SCHEMBL11593448 | 0.87 | KMT2A (0.49) | KMT2ASMN1; SMN2TSHRALOX15USP2 | |
| SCHEMBL773384 | 0.85 | KMT2A (0.66) | KMT2ASMN1; SMN2TSHRALOX15USP2 | |
| SCHEMBL13234849 | 0.82 | KMT2A (0.54) | KMT2ASMN1; SMN2TSHRUSP2ADRB2 | |
| SCHEMBL4294603 | 0.82 | TSHR (0.54) | KMT2ASMN1; SMN2TSHRALOX15USP2 | |
| SCHEMBL17277360 | 0.82 | ADRB2 (0.64) | KMT2ASMN1; SMN2TSHRALOX15ADRB2 | |
| SCHEMBL773103 | 0.82 | ADRB2 (0.64) | KMT2ASMN1; SMN2TSHRALOX15ADRB2 | |
| SCHEMBL17277327 | 0.82 | ADRB2 (0.64) | KMT2ASMN1; SMN2TSHRALOX15ADRB2 | |
| SCHEMBL14301107 | 0.81 | KMT2A (0.62) | KMT2ASMN1; SMN2TSHRALOX15USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008006096-A1 | METAXALONE SYNTHESIS | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-20050075505-A1 | Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone | GANDHI BIREN JAIPRAKASH (IN) | 2005-04-07 | — | — | US | claimed |
| WO-2003061552-A2 | NOVEL PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 5-(3,5-DIMETHYLPHENOXY)METHYL-2-OXAZOLIDINONE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-07-31 | — | — | WO | claimed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3618819-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
| CN-110831584-A | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2018204713-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | EXCIVA UG (HAFTUNGSBESCHRÄNKT) (DE) | 2018-11-08 | — | — | WO | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20050075505-A1 | Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone | GANDHI BIREN JAIPRAKASH (IN) | 2005-04-07 | — | — | US | disclosed |
| US-20050075505-A1 | Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone | GANDHI BIREN JAIPRAKASH (IN) | 2005-04-07 | — | — | US | disclosed |
| WO-2003061552-A3 | NOVEL PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 5-(3,5-DIMETHYLPHENOXY)METHYL-2-OXAZOLIDINONE | SUN PHARMACEUTICAL IND LTD (IN) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003061552-A2 | NOVEL PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 5-(3,5-DIMETHYLPHENOXY)METHYL-2-OXAZOLIDINONE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003061552-A2 | NOVEL PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 5-(3,5-DIMETHYLPHENOXY)METHYL-2-OXAZOLIDINONE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-07-31 | — | — | WO | disclosed |
| EP-0649402-A1 | PRO-DRUG CAPABLE OF RELEASING AN OXAZOLIDINONE AND, IF NEED BE, AN ACETAMIDOPHENOL | UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994001395-A1 | PRO-DRUG CAPABLE OF RELEASING AN OXAZOLIDINONE AND, IF NEED BE, AN ACETAMIDOPHENOL | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 1994-01-20 | — | — | WO | disclosed |
| US-4377582-A | HYPOTENSIVE AGENTS | A. H. ROBINS COMPANY, INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4306065-A | HYPOTENSIVE | A. H. ROBINS COMPANY, INCORPORATED (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | KMT2A 1669/4885SMN1; SMN2 955/4885TSHR 1153/4885 |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | KMT2A 1669/4885SMN1; SMN2 955/4885TSHR 1153/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | KMT2A 572/4885SMN1; SMN2 676/4885TSHR 1538/4885 |
| US-20050075505-A1 | Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone | ODC1, OGFOD1, KMO | KMT2A 552/4885SMN1; SMN2 2568/4885TSHR 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.